Latest Breaking News On - துறை ஆஃப் இம்யூனோ - Page 1 : comparemela.com

The distinctive immuno-oncology RNA therapy targets multiple types of cancers. Scopus BioPharma shares jumped 200% in the stock market on Monday morning. Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the share price Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday morning. The company touched a high of $15.42 per share (£10.90 per share) and is currently exchanging hands at $12.54 per share. In comparison, Scopus had started the year 2021 at a per-share price of $13.41.

United statesMarcin kortylewskiZhua yuScopus biopharmaScopus biopharma incDrug administrationDepartment of immunoNasdaq stock exchangeHodgkin lymphomaBeckman research instituteஒன்றுபட்டது மாநிலங்களில்ஹுவா யூதுறை ஆஃப் இம்யூனோநாஸ்டாக் ஸ்டாக் பரிமாற்றம்ஹாட்ஜ்கின் லிம்போமாபெக்மேன் ஆராய்ச்சி நிறுவனம்